-
-
-
-
-
-
-
Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates
-
-
-
-
-
-
-
Immuneering Announces Participation in November Investor Conferences
-
-
-
-
-
-
-
J&J liable for $572 million in Oklahoma opioid epidemic trial; shares rise
-
-
-
-
-
-
-
London-listed drugmaker Indivior shares crash after U.S. patent blow
-
-
-
-
-
-
-
Teva Pharma (TEVA): Weak Guidance and Upcoming Binary Event Keeps Jefferies at Hold
-
-
-
-
-
-
-
No Read Through to Biogen (BIIB) from Teva (TEVA) Copaxone IPR Result - Jefferies
-
-
-
-
-
-
-
Pre-Open Stock Movers 06/02: (AVEO) (VICL) (TA) Higher; (SOL) (TUBE) (RGLS) Lower (more...)
-
73,346 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

